Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Targeting, Inflammation Development, and Nucleosome Assembly Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for H4C1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | H4C1 Recombinant Protein & Mutant Panel: High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Site-specific PTM mimics (K5Q, K8Q, K12Q, K16Q acetylation; K20 methylation) available for epigenetic reader assays. | View H4C1 Products |
| Gene Delivery | H4C1 Promise-ORF / Lentivirus: Full-length ORF for stable cell line construction and nucleosome assembly studies. | View H4C1 Products |
| Benchmark Ab | Anti-H4C1 Benchmark Antibody (ChIP-grade): Recombinant positive control for western blot, ChIP, and neutralization assays. | View H4C1 Products |
| Validator | H4C1 siRNA Set: For knockdown verification in epigenetic and inflammation assays. | View H4C1 Products |
| Related Target: HDAC1 | Histone deacetylase interacting with H4C1; key eraser enzyme for combination epigenetic therapy. | View HDAC1 Products |
| Related Target: KAT5 (Tip60) | Histone acetyltransferase that specifically acetylates H4; essential for HAT screening. | View KAT5 Products |
| Related Target: H3C1 | Histone H3.1, core nucleosome component for assembly assays and octamer formation. | View H3C1 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Standardized Substrates for Enzymatic Assays | High-purity (>95%) recombinant H4C1 suitable for HAT/HDAC/Methyltransferase screening. |
| Cell Line Stability for Epigenetic Reporter Assays | Lentivirus premade particles for stable cell line construction. |
| Lack of Positive/Negative Controls | Clinical benchmark antibodies and validated siRNA included. |
| False Positives from Endotoxin Contamination | Endotoxin <1EU/ug, strictly controlled for neutralizing antibody assays. |
| Nucleosome Assembly Validation (H4C1-H2A-H2B-H3C1 octamer formation) | Verified N-terminal tail accessibility; native folding by circular dichroism. |
| Post-Translational Modification Specificity (Acetylation/Methylation) | Site-specific mutant panel (K5Q, K8Q, K12Q, K16Q; K20 variants) verified by mass spec. |
| Cross-Variant Selectivity Screening (H4C1 vs H4C2/H4C3/H4C4) | Ortholog/paralog proteins with sequence-verified distinct N-terminal regions. |
| ChIP Assay Standardization | Native folded protein controls with validated secondary structure. |
Live H4C1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Key Mutations & Variants
H4C1 carries clinically relevant mutations associated with developmental disorders. Key variants include:
| Mutation | Context | Evidence |
|---|---|---|
| In TEBIVANED3 | Results in early developmental defects when expressed in zebrafish. | UniProt P62805 VAR_086990 |
| In TEBIVANED1 | Associated with neurological disorder (two entries). | UniProt P62805 VAR_086991, VAR_086992 |
Global Clinical Landscape & Future Outlook
The targeting of core histones including H4C1 represents an emerging frontier in epigenetic drug discovery, shifting from enzyme-centric approaches (HDAC/HAT inhibitors) to direct nucleosome disruption, histone modification-specific modalities, and neutralizing antibodies against extracellular histones in sepsis. First-generation epigenetic therapies face resistance mechanisms, driving next-generation R&D toward synthetic lethality combinations, site-specific histone modification readers, and selective targeted protein degradation (PROTACs). The race for H4C1-related therapeutics is intensifying, with major players focusing on epigenetic modulators and neutralizing antibodies. As first-generation therapies reach the clinic, the next wave of R&D targets PROTACs and combination immunotherapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (HDAC/HAT) | Novartis, Merck | Oncology (Epigenetics) | Enzymatic Assay (Need High-Purity Recombinant H4) |
| Neutralizing Antibody (Extracellular H4) | Startups, Academic Labs | Sepsis, ARDS | Binding/Neutralization Assay (Need Endotoxin <1EU/ug Antigen) |
| PROTAC / Degrader (Epigenetic proteins) | Arvinas, C4 Therapeutics, Kymera | Solid Tumors (Epigenetic addiction) | Mutant H4C1 panel for degradation validation (Need sequence-verified K/R mutations) |
| Molecular Glue (Nucleosome assembly) | Monte Rosa, Celgene/BMS | Hematologic Malignancies | Nucleosome assembly assay (Need high-purity tetramer/octamer components) |
| Epigenetic Reader Inhibitor (Bromodomain, etc.) | Constellation, GSK | Refractory Cancers | PTM-specific binding assays (Need acetyl-mimetic H4C1 variants) |
| Gene Editing (CRISPR-Epigenome) | Editas, Chroma Medicine | Rare Genetic Disorders | Native H4C1 for nucleosome positioning and off-target validation |